| Literature DB >> 35063958 |
Mikaela Mutru1,2, Sanna Isosomppi3, Inka Aho4,2, Kirsi Liitsola3, Henrikki Brummer-Korvenkontio3, Jukka Ollgren3, Oskari Luomala3, Pia Kivelä4,2.
Abstract
PURPOSE: The Finnish HIV Quality of Care Register (FINHIV) was created to: (1) estimate the number of people living with HIV (PLWH) in Finland, (2) evaluate the national level of antiretroviral medication use and viral suppression, (3) examine the change in the HIV epidemic in Finland to pinpoint issues to address and (4) enable evaluation of the health of the PLWH by combining the FINHIV data with other national healthcare data. PARTICIPANTS: The FINHIV includes all people diagnosed or being treated for HIV infection in Finland since 1984. The register was formed in 2020 by combining data from the National Infectious Diseases Register (information from time of diagnosis, data from 1984) and from the 21 HIV Clinics that treat HIV-positive patients in Finland (earliest data from 1998). The register population forms a nationwide, open cohort with yearly updates; currently it consists of 4218 PLWH (including 718 deceased) with HIV diagnosed or treated in Finland 1984-2019. Current rate of new cases is 150 cases/year. FINDINGS TO DATE: From the FINHIV data, we can confirm that Finland has reached the Joint United Nations Programme for HIV/AIDS (UNAIDS) 90-90-90 targets set for 2020, and that the proportion of virally suppressed is constant between all 21 HIV Clinics in Finland, despite their varying size. Linkage to care is estimated at 94.3% of those diagnosed. In contrast to the treatment results, more than half of the PLWH have been diagnosed at a late stage, and the proportion has increased since 2000. FUTURE PLANS: Combinations of FINHIV data with other national healthcare register data in Finland will provide further information on other aspects of the health of the PLWH in a high-resource setting (eg, comorbidities, sexual health and use of healthcare resources). Additionally, implementation of patient-reported experience and outcome measures within the FINHIV is ongoing. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: HIV & AIDS; epidemiology; infectious diseases
Mesh:
Substances:
Year: 2022 PMID: 35063958 PMCID: PMC8785158 DOI: 10.1136/bmjopen-2021-053287
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Formation of the current (1984–2019) Finnish HIV Quality of Care Register (FINHIV) cohort.
Information sources for Finnish HIV Quality of Care Register
| Collected piece of information | Source of information (maintainer) | |||
| National Infectious Diseases Register (THL*) | Local register or medical records (HIV Clinics) | Population Information System (DVV†) | Finnish Immigration Service‡ | |
| Personal identity code | x | x§ | x | x |
| Sex | x | x | x | x |
| Date of birth | x | x | x | |
| Date of death | x | x | ||
| Country of birth | x | x | x | |
| Date of immigration | x | x | x | |
| Date of emigration | x | x | x | |
| Mode of transmission | x | x | ||
| Country of transmission | x | x | ||
| Date of HIV diagnosis | x | x | ||
| Date of AIDS diagnosis | x | x | ||
| AIDS-defining diagnosis | x | x | ||
| Hepatitis C antibodies (positive/negative) | x | x | ||
| Hepatitis B S-antigen (positive/negative) | x | x | ||
| CD4 +cell count at diagnosis (cells/μL) | x | x | ||
| HIV viral load (copies/mL) at diagnosis | x | x | ||
| Treating HIV Clinic | x | |||
| Start of follow-up date | x§ | |||
| End of follow-up date | x | |||
| CD4 +cell count during follow-up (cells/μL), with dates | x§ | |||
| HIV viral load during follow-up (copies/mL), with dates | x§ | |||
| HLAB5701¶ | x | |||
| Date of drug resistance test | x | |||
| Antiretroviral medication | x§ | |||
| Starting date of each medication | x§ | |||
| Ending date of each medication | x§ | |||
| Blood pressure | x | |||
| Height | x | |||
| Weight | x | |||
| Smoking (yes/no, has quit/no, never) | x | |||
| Additional laboratory test results** | x | |||
*Finnish Institute for Health and Welfare.
†Digital and Population Data Services Agency.
‡For cases born abroad, dates of immigration and emigration (if available) were collected as a one-time data transfer in August 2020 for the initial register formation; possibly included in further updates.
§Minimum requirements of information from HIV Clinics. For CD4 +cell count, HIV viral load and antiretroviral medication, latest dates were the minimum requirement.
¶Presence of major histocompability complex class I allele HLAB5071 (abacavir hypersensitivity).
**Collected from HIV Clinics that use a local register; for example, blood sugar and cholesterol levels.
Characteristics of current (1984–2019) Finnish HIV Quality of Care Register population
| Information | n | % |
| Population | 4218 | |
| Valid PIC* | 3797 | 90.0 |
| Women | 1192 | 28.3 |
| Age at diagnosis | Mean 36.7 years | Std 12.3 years |
| CD4 +cell count at diagnosis available† | 1998 | 47.4 |
| ≥500 (cells/μL) | 613 | 30.7† |
| 350–499 (cells/μL) | 403 | 20.2† |
| 200–349 (cells/μL) | 403 | 20.2† |
| <200 (cells/μL) | 579 | 29.0† |
| Diagnosed AIDS | 865 | 20.5 |
| Deceased | 718 | 17.0 |
| In follow-up at end of 2019‡ | 2763 | 65.5 |
| Mode of transmission | ||
| Heterosexual | 1921 | 45.5 |
| MSM§ | 1344 | 31.9 |
| IDU¶ | 442 | 10.5 |
| Vertical transmission | 40** | 0.95** |
| Other/unknown | 471 | 11.2 |
| Country of birth | ||
| Finland | 2561 | 60.7 |
| Other | 1538 | 36.5 |
| Unknown | 119 | 2.8 |
| Hepatitis C antibodies | ||
| Positive | 380 | 9.0 |
| Negative | 2261 | 53.6 |
| Unknown | 1577 | 37.4 |
| Hepatitis B S-antigen | ||
| Positive | 91 | 2.2 |
| Negative | 2546 | 60.4 |
| Unknown | 1581 | 37.5 |
*Personal identity code. Invalidity usually due to recent immigration.
†If measured in Finland 0–90 days after date of HIV diagnosis. Percentages reported as proportions of those with the cell count available (n=1998).
‡Alive and living in Finland with HIV viral level measured in 2019.
§Men who have sex with men.
¶Intravenous drug use.
**Of these, only three transmissions (0.07% of the population) occurred in Finland.
IDU, Intravenous drug use; MSM, Men who have sex with men; PIC, personal identity code.
Figure 2Virally suppressed1 of those on antiretroviral treatment in Finnish HIV Clinics in 2019. Figure reproduced from9 with permission. The percentage of those virally suppressed is shown with 95% CIs. There are 21 HIV clinics in Finland; the patients of the two smallest clinics (<5 patients) are included in the results of the nearest larger clinic. 1HIV-1 RNA <50 copies/mL. 2The Joint United Nations Programme for HIV/AIDS (UNAIDS) target for years 2020 and 2030.